$FuboTV(FUBO.US$ Has seen it's stock price decline to book value levels of just $1.24, the company has a excellent customer base, the subs have grown to 1.5 Million, which is 18% more than 1 year ago. FUBO will be profitable in 2025. With the growing amount of subs & the value of customer acquistion cost makes FUBO a clear takeove target & this year would be the time to buyout FUBO. I would expect an offer of around $3.7...
16
5
$Esperion Therapeutics(ESPR.US$ Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, have positioned it as defininte acquistion target for larger pharmaceutical companies. Esperion's drugs NEXLIZET and NEXLETOL now have primary prevention labels, NEXLIZET will soon become the drug of choice over a PCSK9 inhibitor says Texas based HeartPlace leading Cardio...
12
$Esperion Therapeutics(ESPR.US$ Esperion (ESPR) stock price has dropped from a recent high of $3.40 a share to $2.31 on FALSE claims of dilution. The price drop offers an amazing buying opportunity.
Huge News On Mar 25.2024 U.S. FDA Approved Broad Labels for NEXLIZET and NEXLETOL, now regular doctors can prescribe and Insurance will...
Huge News On Mar 25.2024 U.S. FDA Approved Broad Labels for NEXLIZET and NEXLETOL, now regular doctors can prescribe and Insurance will...
3
03/28/2024 $BigBear.ai Holdings(BBAI.US$ BigBear Ai Started At Buy with $6 Price Target. BBAI focuses on artificial intelligence and machine learning solutions for government and commercial clients: BBAI has a much lower valuation on a price to sales ratio in the sector, and promising technology are attractive. Palantir $Palantir(PLTR.US$ trades at price to sales ratio P/S of 24, SnowFlake $Snowflake(SNOW.US$ trades at price to sales ratio P/S of 1...
8
life is a blessing
commented on
$BigBear.ai Holdings(BBAI.US$ It is now time to BUY. This A.i company had a recent run up to near $5 a share, the stock price has sold off to $2.07 and is now in the extreme oversold zone. My technical analysis A.i program suggests the stock will rebound in the near term to the $2.50. BBAI reported earnings and guided higher revenue for 2024 from $195 million to $210 million, The growth is very good and will only get better from here. Motley Fool, a conservative g...
3
4
$Blink Charging(BLNK.US$ SHORT SQUEEZE Indicater ranks BLNK at 81% Squeeze potential with $5+ near term target. BLNK has a current stock price of $3.11 and a book value of $3.28 per share. 39% of BLNK's float is sold short. BLNK has exceptional revenue growth and raised it's full year well above expectations. NeedHam analyst raised rating to BUY with a $7 price target. BLNK average price target is $9.50 and the high price target is $25 a share. BLNK has the po...
1
2
life is a blessing
commented on
$TRITIUM DCFC LIMITED(DCFC.US$ In my opinion, DCFC stock will go up 500% in 2024. I know the EV charging companies have been beaten up, DCFC trades well below all others on Price to Sales ratio. News just came out on Bridge loan at 15%, the company is in the process of closing the factory in Brisbane Australia and focusing on it's factory in the U.S, company has backlog of ove...
11
life is a blessing
commented on
$TRITIUM DCFC LIMITED(DCFC.US$ EV charging company DCFC Source says DCFC is about to be aquired, taken private for $0.90 to $1.40 per share. The press release Nov 7th "DCFC closing Brisbane factory and moving operations to its Factory in the U.S.A. and plans to be profitable in 2024" Article on Dec 1st. Talks of Taiwanese electronics company Lite-On Technology and Saudi Arabian investment fund interested in taking a position in the company, and or acquiring the company. Also Billionaire Trevor ...
1
1
$Esperion Therapeutics(ESPR.US$ Some great info on Esperion, its FDA approved drugs Nexletol which is Bempedoic Acid and Nexlizet drug (Bempedoic Acid and Ezetimibe) showing why Esperion will be a blockbuster.
Bempedoic acid for statin intolerant patients? This #2023 trial is the first positive outcomes trial for this lipid lowering drug — and THE FIRST to SHOW non-statin benefit in primary prevention. CLEAR Outcomes Trial, NEJM 2023
https://twitter.com/CardiacTrials/status/172595635110769067...
Bempedoic acid for statin intolerant patients? This #2023 trial is the first positive outcomes trial for this lipid lowering drug — and THE FIRST to SHOW non-statin benefit in primary prevention. CLEAR Outcomes Trial, NEJM 2023
https://twitter.com/CardiacTrials/status/172595635110769067...
1
1
life is a blessing
commented on
There are so many aspect to technical analysis(TA) that it can be very overwhelming and intimidating to anybody that is new to investing. With hundreds of different technical indicators and strategies it can be difficult to decide where to start learning technical analysis.
The most important aspects of technical analysis are actually the most basic fundamentals of TA. They are the first thing you should learn in TA. Price action, volume, and the overall tr...
The most important aspects of technical analysis are actually the most basic fundamentals of TA. They are the first thing you should learn in TA. Price action, volume, and the overall tr...
![The Many Aspects of Technical Analysis](https://ussnsimg.moomoo.com/feed_image/70107943/e21f33699d973614b741d20d70343f88.jpg/thumb)
![The Many Aspects of Technical Analysis](https://ussnsimg.moomoo.com/feed_image/70107943/c3a4f13d687d398ca460a711506b376c.jpg/thumb)
![The Many Aspects of Technical Analysis](https://ussnsimg.moomoo.com/feed_image/70107943/6526c047c65334adb508de89db7e6c16.jpg/thumb)
+2
210
66